MX2021011272A - Composiciones y metodos para tratar el cancer. - Google Patents

Composiciones y metodos para tratar el cancer.

Info

Publication number
MX2021011272A
MX2021011272A MX2021011272A MX2021011272A MX2021011272A MX 2021011272 A MX2021011272 A MX 2021011272A MX 2021011272 A MX2021011272 A MX 2021011272A MX 2021011272 A MX2021011272 A MX 2021011272A MX 2021011272 A MX2021011272 A MX 2021011272A
Authority
MX
Mexico
Prior art keywords
methods
compositions
treating cancer
egfr
present disclosure
Prior art date
Application number
MX2021011272A
Other languages
English (en)
Inventor
Michael E Jung
David A Nathanson
Jonathan Tsang
Lorenz Urner
Peter M Clark
Timothy F Cloughesy
Gyudong Kim
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of MX2021011272A publication Critical patent/MX2021011272A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente descripción se refiere a compuestos que son capaces de penetrar hasta la barrera hematoencefálica para modular la actividad de la tirosina cinasa EGFR. La descripción se refiere además a métodos para tratar el glioblastoma y otros cánceres mediados por EGFR. La descripción se refiere además a métodos para tratar el glioblastoma y otros cánceres mediados por EGFR que se ha determinado que tienen un metabolismo de glucosa alterado en presencia de inhibidores. La presente descripción también proporciona métodos para administrarle a un sujeto un inhibidor del metabolismo de la glucosa y un estabilizador de p53 citoplasmática.
MX2021011272A 2019-03-15 2020-03-13 Composiciones y metodos para tratar el cancer. MX2021011272A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962819322P 2019-03-15 2019-03-15
US201962904241P 2019-09-23 2019-09-23
PCT/US2020/022743 WO2020190765A2 (en) 2019-03-15 2020-03-13 Compositions and methods for treating cancer

Publications (1)

Publication Number Publication Date
MX2021011272A true MX2021011272A (es) 2021-10-01

Family

ID=72521289

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011272A MX2021011272A (es) 2019-03-15 2020-03-13 Composiciones y metodos para tratar el cancer.

Country Status (15)

Country Link
US (2) US11377451B2 (es)
EP (1) EP3938354A4 (es)
JP (1) JP7474269B2 (es)
KR (1) KR20210151820A (es)
CN (2) CN115215808A (es)
AU (1) AU2020241703A1 (es)
BR (1) BR112021018295A2 (es)
CA (1) CA3133688A1 (es)
CL (1) CL2021002409A1 (es)
CO (1) CO2021013496A2 (es)
CR (1) CR20210498A (es)
IL (1) IL286350A (es)
MX (1) MX2021011272A (es)
SG (1) SG11202109662YA (es)
WO (1) WO2020190765A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111868039A (zh) * 2017-09-26 2020-10-30 加利福尼亚大学董事会 用于治疗癌症的组合物和方法
KR20210151820A (ko) 2019-03-15 2021-12-14 더 리전트 오브 더 유니버시티 오브 캘리포니아 암을 치료하기 위한 조성물 및 방법
US20240058340A1 (en) * 2020-09-21 2024-02-22 The Regents Of The University Of California Compositions and methods for treating cancer
US20230364091A1 (en) * 2020-09-21 2023-11-16 The Regents Of The University Of California Compositions and methods for treating cancer
WO2022155311A1 (en) * 2021-01-14 2022-07-21 The Regents Of The University Of California Methods and systems for analysis of drug target engagement and treatment of cancer
US20240165132A1 (en) * 2021-05-12 2024-05-23 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
CN113307799B (zh) * 2021-05-21 2022-07-19 大连医科大学 一种检测葡萄糖醛酸转移酶1a1荧光探针及其应用
WO2023049312A1 (en) * 2021-09-23 2023-03-30 Erasca, Inc. Egfr inhibitor polymorph forms
WO2023244639A1 (en) * 2022-06-14 2023-12-21 The Regents Of The University Of California Methods of predicting cns cancer response to treatment with egfr inhibitors
WO2024081447A1 (en) * 2022-10-14 2024-04-18 The Regents Of The University Of California Egfr inhibitors for treating lung cancer

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5538325A (en) * 1978-09-11 1980-03-17 Sankyo Co Ltd 4-anilinoquinazoline derivative and its preparation
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
KR100397792B1 (ko) * 2001-06-28 2003-09-13 한국과학기술연구원 4-(페닐아미노)-[1,4]디옥사노[2,3-ｇ]퀴나졸린 유도체 및그의 제조방법
CN1854130B (zh) 2005-04-15 2011-04-20 中国医学科学院药物研究所 喹唑啉衍生物、及其制法和药物组合物与用途
WO2008046242A1 (fr) 2006-10-16 2008-04-24 Institute Of Mataria Medica, Chinese Academy Of Medical Sciences Nouveaux dérivés quinazolines, leurs procédés de préparation et leurs utilisations
US8916574B2 (en) 2009-09-28 2014-12-23 Qilu Pharmaceutical Co., Ltd. 4-(substituted anilino)-quinazoline derivatives useful as tyrosine kinase inhibitors
ITPD20110091A1 (it) 2011-03-24 2012-09-25 Univ Padova Inibitori multitirosinchinasi utili per le patologie correlate: modelli farmacoforici, composti identificati tramite questi modelli, metodi per la loro preparazione, la loro formulazione e il loro impiego terapeutico.
JP6559785B2 (ja) * 2014-12-15 2019-08-14 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ｅｇｆｒ及びｐｉ３ｋの小分子阻害剤
CN105017163A (zh) 2015-08-25 2015-11-04 佛山市赛维斯医药科技有限公司 双乙氧基苯并喹唑啉类酪氨酸激酶抑制剂、制备方法及其用途
US10473255B2 (en) 2015-12-29 2019-11-12 Ge-Hitachi Nuclear Energy Americas Llc Reactor pressure vessel including pipe restraint device, and/or a pipe restraint device
EP3400216A4 (en) 2016-01-06 2019-08-14 Trillium Therapeutics Inc. NOVEL FLUORINATED QUINAZOLINE DERIVATIVES AS INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)
CN106432202B (zh) 2016-09-22 2019-04-02 郑州大学第一附属医院 喹唑啉类衍生物及其应用
CN111868039A (zh) 2017-09-26 2020-10-30 加利福尼亚大学董事会 用于治疗癌症的组合物和方法
KR20210151820A (ko) 2019-03-15 2021-12-14 더 리전트 오브 더 유니버시티 오브 캘리포니아 암을 치료하기 위한 조성물 및 방법
WO2022061299A1 (en) 2020-09-21 2022-03-24 The Regents Of The University Of California Non-invasive functional companion assays for oncogene targeted therapy for brain cancer
US20230364091A1 (en) 2020-09-21 2023-11-16 The Regents Of The University Of California Compositions and methods for treating cancer
US20240058340A1 (en) 2020-09-21 2024-02-22 The Regents Of The University Of California Compositions and methods for treating cancer
WO2023049312A1 (en) 2021-09-23 2023-03-30 Erasca, Inc. Egfr inhibitor polymorph forms
WO2023244639A1 (en) 2022-06-14 2023-12-21 The Regents Of The University Of California Methods of predicting cns cancer response to treatment with egfr inhibitors

Also Published As

Publication number Publication date
CN113811528A (zh) 2021-12-17
WO2020190765A3 (en) 2020-11-26
EP3938354A4 (en) 2022-12-28
WO2020190765A2 (en) 2020-09-24
CR20210498A (es) 2022-01-11
SG11202109662YA (en) 2021-10-28
CN115215808A (zh) 2022-10-21
CO2021013496A2 (es) 2022-01-17
JP7474269B2 (ja) 2024-04-24
US20230115366A1 (en) 2023-04-13
US20220064177A1 (en) 2022-03-03
KR20210151820A (ko) 2021-12-14
JP2022526266A (ja) 2022-05-24
AU2020241703A1 (en) 2021-10-14
US11377451B2 (en) 2022-07-05
EP3938354A2 (en) 2022-01-19
BR112021018295A2 (pt) 2021-11-23
CA3133688A1 (en) 2020-09-24
CL2021002409A1 (es) 2022-06-17
IL286350A (en) 2021-10-31

Similar Documents

Publication Publication Date Title
MX2021011272A (es) Composiciones y metodos para tratar el cancer.
AU2018368731A8 (en) Combination therapies
PH12019501116A1 (en) Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20
MX2023010430A (es) Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten con mutacion g12d (kras g12d).
MX2018013848A (es) Combinacion de anticuerpos anti-pd-1s y radiacion para tratar cancer.
EA200970953A1 (ru) СПЕЦИФИЧНЫЕ ИНГИБИТОРЫ PDGFRβ
EA201290139A1 (ru) Модуляторы кальциевого канала, активируемого высвобождением кальция, представляющие собой производные пиразола, и способы лечения немелкоклеточного рака легких
MX363188B (es) Identificación de pacientes con necesidad de coterapia del inhibidor de pd-l1.
MY152948A (en) 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
WO2012016133A3 (en) Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
TN2010000204A1 (en) Kinesin inhibitors as cancer therapeutics
MX2021014455A (es) Inhibidores de proteina cinasas dependientes de adn.
AU2010266004A8 (en) Method of treating cancer with Dll4 antagonist and chemotherapeutic agent
WO2009137543A3 (en) Methods for breast cancer screening and treatment
MX2018001507A (es) Composiciones y metodos para tratar cánceres asociados con la activacion del etbr.
MX2019012176A (es) Metodos de combinacion de chk1(sra737)/parpi para inhibir el crecimiento tumoral.
MX2021002805A (es) Terapias de combinacion.
JOP20220107A1 (ar) مثبطات egfr تفارغية وطرق استخدامها
MX2023010429A (es) Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten (kras).
AU2018271862A1 (en) Combination therapy
AU2018380132A8 (en) Tubulin inhibitors
PH12020500665A1 (en) Pladienolide derivatives as spliceosome targeting agents for treating cancer
MX2022010860A (es) Terapia combinada que comprende inhibidores de axl/mer y pd-1/pd-l1.
PH12021551276A1 (en) Combination therapy for the treatment of cancer
MX2020006224A (es) Metodos y terapia combinada para el tratamiento del cancer.